ISK received the FDA’s approval to start Phase 1b/2a with AML patientsJanuary 9, 2020
Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumorsFebruary 17, 2022
The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.
PHASE 1B/2A Clinical trial startedApril 13, 2021
Cooperation with Harvard Medical School (MGH)October 27, 2019
ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases